share_log

BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

BTIG 维持对Pear Therapeutics的买入,将目标价下调至
Benzinga Real-time News ·  2022/08/12 09:52

BTIG analyst Marie Thibault maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $11 to $5.

BTIG分析师玛丽·蒂博维持Pear Therapeutics(纳斯达克股票代码:PEAR)的买入,并将目标股价从11美元下调至5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发